Gore v. Medtronic stent graft patent suit thrown out; Covidien rolls out new respiratory monitor;

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

 @MarkHFierce: EndoGastric pulled in another $13M in new venture finding for a device designed to help treat chronic acid reflux. Press release | Follow @MarkHFierce

 @DamianFierce: Lawmakers, device industry on the same page as FDA user fee clears House, moves toward adoption. Article | Follow @DamianFierce

> A U.S. District Court judge threw out a 2010 lawsuit that accused Medtronic ($MDT) of violating W.L. Gore-held patents regarding the manufacturing of stent grafts. Story

> Covidien ($COV) is launching the Nellcor SpO2 respiratory monitor, designed to work with Philips Healthcare's IntelliVue patient monitoring platform. News

> Kansas company Post-T-Vac may have run up as much as $4.2 million in potentially bogus Medicare claims for the company's penis pumps, the Department of Health and Human Services inspector general alleges. Story

> Bio-Light Israeli Life Sciences Investments will acquire an ocular implant from a U.S. company that enables the sustained release of drugs to treat glaucoma. Story

> ReShape Medical has appointed former Allergan and Bausch + Lomb executive Robert E. Grant to its board of directors. The company is developing a non-surgical weight loss device. Release

Biotech News

 @FierceBiotech: See the faces of biotech leaders at BIO2012 in our convention slideshow. Slideshow | Follow @FierceBiotech

 @JohnCFierce: Interesting to note that if the ACA is tossed out by the Supremes, there goes 12 years of exclusivity for biologics and biosimilars pathway. Poof. | Follow @JohnCFierce

 @RyanMFierce: My take from BIO 2012 on how the pharma herd faces hurdles with pricey new drugs. Report | Follow @RyanMFierce

> Pozen shares slide after FDA questions study for aspirin combo. More

> House rushes through approval of new PDUFA legislation. News

> Onyx clears big hurdle in high-stakes gamble on early carfilzomib approval. Article

> FDA panel turns thumbs down on Sanofi's anti-clotting drug. Story

Pharma News

 @FiercePharma: AstraZeneca's Brilinta = lower healthcare costs, even at brand prices, finds cost-based analysis of PLATO data. More | Follow @FiercePharma

> Celgene's hopes for Revlimid stymied by regulatory setback. Story

> J&J close to $1.5B-plus Risperdal settlement, but not there yet. Article

> Is Madagascar 3's friendly lion a dangerous drug spokesman? More

> Anti-overtime ruling a disguised blessing for reps, recruiters say. Report

Pharma Manufacturing News

> Shasun cutting costs with Indian intermediates plant. Article

> Bard, Sartorius invest nearly $70M in Puerto Rico plants. Story

> CSL confirms convulsions appear tied to Fluvax manufacturing. More

Vaccines News

> HPV DNA vax should enter the clinic in 2013. More

> Therapeutic cancer vaccines: Optimism for the future at BIO2012. Article

> Anthrax vax to move into new Phase II trials. Story

> Genocea's HSV-2 vax to hit the clinic. News

CRO News

 @NesaNFierce: Not shocked that the Philippines and Indonesia are eyed as emerging leaders in outsourcing. Population means a lot. More | Follow @NesaNFierce

> Can Russia emerge as a global biotech and manufacturing leader? More

> Filling services help Dalton seal manufacturing deal with Clarity. Article

> Biopharma looks at pros and cons of CMOs when debating in-house versus outsourcing. News

And Finally... Aneuclose, a Minnesota device startup, is developing a mesh device (combined with microsponges) for use as a treatment of narrow-neck aneurysms. Story

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.